Seeing Is Believing
Currently out of the existing stock ratings of Dave Dai, 83 are a BUY (100%).
Analyst Dave Dai, currently employed at SMBC NIKKO,
Dave Dai’s has documented 4 price targets and ratings displayed on 5 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ACET, Adicet Bio at 31-Mar-2022.
Analyst best performing recommendations are on INBX (INHIBRX ).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
2 months 10 days ago
(15-May-2025)
4/6 (66.67%)
$4.74 (21.29%)
118
Buy
$46
$21.55 (88.14%)
$46
2 years 4 months 18 days ago
(07-Mar-2023)
0/4 (0%)
$22.03 (91.91%)
Buy
$40
$9.67 (31.88%)
3 years 4 months 9 days ago
(16-Mar-2022)
0/1 (0%)
$17.23 (75.67%)
Buy
$53
$21.73 (69.49%)
3 years 8 months 16 days ago
(10-Nov-2021)
1/2 (50%)
$10.05 (23.40%)
271
Buy
$60
$41.65 (226.98%)
$30
3 years 9 months 13 days ago
(12-Oct-2021)
1/2 (50%)
$19.48 (75.48%)
78
What Year was the first public recommendation made by Dave Dai?